作者:
Martin-Algarra, Salvador [1]
;
Hinshelwood, Rebecca [2]
;
Mesnage, Soizick [3]
;
Cebon, Jonathan [4]
;
Ferrucci, Pier Francesco [5]
;
Aglietta, Massimo [6]
;
Neyns, Bart [7]
;
Chiarion-Sileni, Vanna [8]
;
Lindsay, Colin R. [9]
;
Del Vecchio, Michele [10]
;
Linardou, Helen [11]
;
Merelli, Barbara [12]
;
Tonini, Giuseppe [13]
;
Atkinson, Victoria [14]
;
Freivogel, Klaus [15]
;
Stein, Dara [16]
;
Dalland, Lindi [17]
;
Lau, Mike [18]
;
Legenne, Philippe [19]
;
Queirolo, Paola [20]
;
Millward, Michael
作者单位:
Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia
[1]
NHS Greater Glasgow & Clyde, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2]
Univ Torino, Candiolo Canc Inst, Dept Med Oncol, Turin, Italy
[3]
Univ Queensland, Gallipoli Med Res Fdn, Brisbane, Qld, Australia
[4]
Novartis Norge AS, Oslo, Norway
[5]
IRCCS San Martino IST, UOC Oncol Med, Genoa, Italy
[6]
Novartis Pharma AG, Basel, Switzerland
[7]
Ist Oncol Veneto, IRCCS, Melanoma & Esophageal Canc Unit, Padua, Italy
[8]
Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[9]
Metropolitan Hosp, Dept Oncol 1, Athens, Greece
[10]
Auckland City Hosp, Auckland, New Zealand
[11]
Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium
[12]
Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy
[13]
European Inst Oncol, Melanoma Unit, Milan, Italy
[14]
Univ Navarra, Clin Univ Navarra, Dept Med Oncol, Pamplona, Spain
[15]
ASST Papa Giovanni XXIII, Dept Med Oncol, Bergamo, Italy
[16]
Westmead Hosp, Crown Princess Mary Canc Ctr, Dept Med Oncol, Westmead, NSW, Australia
[17]
Univ British Columbia, Montreal, PQ, Canada
[18]
UBC, Lorrach, Germany
[19]
Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[20]
发布时间
2020-07-29